Compass Pathways (CMPS) Stock Price, News & Analysis

Company Overview

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.

In addition to its lead depression program, Compass Pathways is exploring broader applications of psychedelic-assisted therapies in areas such as anorexia nervosa and other mood disorders. The company has built a scalable manufacturing process for synthetic psilocybin and established a network of trained therapists and research sites across Europe and North America. Compass also leverages digital tools to capture patient-reported outcomes and physiological data, supporting personalized treatment protocols and enhancing safety monitoring throughout clinical studies.

Since its initial public offering in September 2020, Compass Pathways has advanced its pipeline through rigorous clinical partnerships and academic collaborations. The leadership team is led by co-founder and CEO George Goldsmith, who has guided the company through regulatory milestones and strategic alliances. With a board of directors comprising experts in neuroscience, clinical research, and life sciences commercialization, Compass remains committed to transforming the treatment paradigm for mental health by combining innovative science, patient-centered care, and robust regulatory engagement.

Key Stats

• Today's Range: $12.20 to $13.00
• 50-Day Range: $5.53 to $14.19
• 52-Week Range: $2.35 to $14.76
• Volume: 2.35 million shs
• Average Volume: 3.61 million shs
• Market Capitalization: $1.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.90
• Consensus Rating: Buy

Compass Pathways Stock Analysis - MarketRank™

Compass Pathways scored higher than 64% of companies evaluated by MarketBeat, and ranked 332nd out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Compass Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Compass Pathways has a consensus price target of $22.90, representing about 78.7% upside from its current price of $12.81.

Amount of Analyst Coverage

Compass Pathways has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compass Pathways are expected to decrease in the coming year, from ($1.24) to ($1.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compass Pathways is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compass Pathways is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.59% of the float of Compass Pathways has been sold short.

Short Interest Ratio / Days to Cover

Compass Pathways has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Compass Pathways has recently decreased by 4.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compass Pathways does not currently pay a dividend.

Dividend Growth

Compass Pathways does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.64

News Sentiment

Compass Pathways has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Compass Pathways this week, compared to 4 articles on an average week.

Search Interest

Only 12 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

MarketBeat Follows

10 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compass Pathways insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.82% of the stock of Compass Pathways is held by insiders.

Percentage Held by Institutions

46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMPS
• CIK: 1816590
• Web: www.compasspathways.com
• Phone: 716-676-6461
• Fax: N/A
• Employees: 120
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Compass Pathways: $22.90
• High Price Target: $70.00
• Low Price Target: $14.00
• Potential Upside/Downside: +81.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$287.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.07%
• Return on Assets: -11.40%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 3.32
• Quick Ratio: 3.32

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -23.00

Miscellaneous

• Outstanding Shares: 134,950,000
• Free Float: 131,143,000
• Market Cap: $1.71 billion
• Optionable: Optionable
• Beta: 2.50